A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

← catalyst calendar

NCT06764875 · readout in 982 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Single · Treatment

Enrollment

840estimated

Sites

293

Countries

Argentina, Australia, Austria +25

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-03-01

actual

When the study began enrolling

Primary completion

2029-04-27

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-12-09

estimated

The whole study's end, after follow-up

First posted

2025-01-09

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-16

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

HER2-positive Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions

Drug: Rilvegostomig — also filed as AZD2936
Drug: Trastuzumab deruxtecan — also filed as T-DXd, DS-8201
Drug: Trastuzumab
Drug: Pembrolizumab
Drug: 5-fluorouracil — also filed as 5-FU
Drug: Capecitabine
Drug: Cisplatin
Drug: Oxaliplatin

Primary outcomes

what the primary-completion date above is the date OF

Progression free survival (PFS)

measured Up to approximately 6 years

Overall Survival (OS)

measured Up to approximately 6 years

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed